Shanghai Kaibao Pharmaceutical Co., Ltd. (300039) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 2.31% and Operating profit at 12.48% over the last 5 years

Negative results in Mar 25

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 6,395 Million (Mid Cap)

P/E

18.00

Industry P/E

Dividend Yield

1.64%

Debt Equity

-0.45

Return on Equity

8.22%

Price to Book

1.50

Revenue and Profits:

Net Sales:

200 Million

(Quarterly Results - Jun 2025)

Net Profit:

38 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

6.71%

6 Months

3.33%

1 Year

-4.12%

2 Years

-9.94%

3 Years

-4.4%

4 Years

36.97%

5 Years

23.95%

Shanghai Kaibao Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

2.31%

EBIT Growth (5y)

12.48%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.21

Sales to Capital Employed (avg)

0.37

Tax Ratio

15.03%

Dividend Payout Ratio

27.85%

Pledged Shares

Institutional Holding

ROCE (avg)

8.20%

ROE (avg)

6.40%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.50

EV to EBIT

13.76

EV to EBITDA

12.38

EV to Capital Employed

1.91

EV to Sales

3.63

PEG Ratio

18.24

Dividend Yield

1.64%

ROCE (Latest)

13.90%

ROE (Latest)

8.22%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -42.45% vs -8.53% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -29.85% vs -2.55% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "200.50",
          "val2": "348.40",
          "chgp": "-42.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "40.00",
          "val2": "70.10",
          "chgp": "-42.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.70",
          "val2": "-5.30",
          "chgp": "86.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "37.60",
          "val2": "53.60",
          "chgp": "-29.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "155.30%",
          "val2": "175.30%",
          "chgp": "-2.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -7.61% vs 42.49% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 14.68% vs 71.96% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,450.60",
          "val2": "1,570.10",
          "chgp": "-7.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "388.70",
          "val2": "347.30",
          "chgp": "11.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.10",
          "val2": "-13.70",
          "chgp": "108.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "374.90",
          "val2": "326.90",
          "chgp": "14.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "242.90%",
          "val2": "197.20%",
          "chgp": "4.57%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

200.50

348.40

-42.45%

Operating Profit (PBDIT) excl Other Income

40.00

70.10

-42.94%

Interest

0.00

Exceptional Items

-0.70

-5.30

86.79%

Consolidate Net Profit

37.60

53.60

-29.85%

Operating Profit Margin (Excl OI)

155.30%

175.30%

-2.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -42.45% vs -8.53% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -29.85% vs -2.55% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1,450.60

1,570.10

-7.61%

Operating Profit (PBDIT) excl Other Income

388.70

347.30

11.92%

Interest

0.10

Exceptional Items

1.10

-13.70

108.03%

Consolidate Net Profit

374.90

326.90

14.68%

Operating Profit Margin (Excl OI)

242.90%

197.20%

4.57%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -7.61% vs 42.49% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 14.68% vs 71.96% in Dec 2023

All Annual Results

Company CV

About Shanghai Kaibao Pharmaceutical Co., Ltd.

Shanghai Kaibao Pharmaceutical Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available